Get the Stockscreener App
1.865
1.36%
0.025
After Hours:
1.87
0.005
+0.27%
Inventiva Adr stock is traded at $1.865, with a volume of 26,976.
It is up +1.36% in the last 24 hours and down -17.66% over the past month.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
See More
Previous Close:
$1.84
Open:
$1.91
24h Volume:
26,976
Relative Volume:
3.00
Market Cap:
$98.75M
Revenue:
$18.85M
Net Income/Loss:
$-119.67M
P/E Ratio:
-0.9179
EPS:
-2.0318
Net Cash Flow:
$-89.09M
1W Performance:
-14.84%
1M Performance:
-17.66%
6M Performance:
-48.48%
1Y Performance:
-55.60%
1-Day Range:
$1.83
$1.92
1-Week Range:
$1.53
$2.1906
52-Week Range:
$1.53
$4.75
Inventiva Adr Stock (IVA) Company Profile
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-23 | Initiated | Canaccord Genuity | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-19-23 | Upgrade | Societe Generale | Sell → Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Nov-15-22 | Downgrade | Societe Generale | Buy → Sell |
| Mar-08-21 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Initiated | ROTH Capital | Buy |
| Aug-04-20 | Initiated | Guggenheim | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Inventiva Adr Stock (IVA) Latest News
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results - GlobeNewswire Inc.
Why Are Criminals Still in Power? 151 Lawmakers with Charges of Crimes Against Women Continue to Hold Office! Is This the End of Integrity in Indian Politics? - Inventiva
Inventiva Reports Preliminary 2024 First-Half Financial Information¹ - GlobeNewswire Inc.
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving PremarketParamount ... - Benzinga
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and ... - GlobeNewswire Inc.
DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024 - GlobeNewswire Inc.
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024 - GlobeNewswire Inc.
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) - Yahoo Finance
Assemblée Générale Mixte du 20 juin 2024 - GlobeNewswire Inc.
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024 - GlobeNewswire Inc.
Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activités - GlobeNewswire Inc.
Inventiva's Key Drug Trial Advances PositivelyTipRanks.com - TipRanks
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH - GlobeNewswire Inc.
Inventiva SA ADR Announces Key General MeetingTipRanks.com - TipRanks
Inventiva's Lanifibranor Shows Promise in MASH/NASH TreatmentTipRanks.com - TipRanks
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor - GlobeNewswire Inc.
Inventiva announces the implementation of an At-The-Market program in the United States - The Globe and Mail
Inventiva's Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor EarningsTipRanks.com - TipRanks
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F ») - GlobeNewswire Inc.
Will Election Commission Make Sure That Elections In 2024 Will Be Completely Fair? - Inventiva
Inventiva SA ADR Announces Optimistic 2023 ResultsTipRanks.com - TipRanks
Inventiva’s LEGEND Trial Shows Promising Results - TipRanks
Is SBI's Demand For Extra Time To Disclose Details Of Electoral Bonds 1 Attempt To Hide The Doings And Doers Of ‘Great Political Chanda’? - Inventiva
IVA Stock Quote Price and Forecast - CNN
Supreme Court To Hear Plea Against Electoral Bonds From October 31 - Inventiva
National Parties Declare Assets Worth Rs 8,829 Crore In 2021-22: Report - Inventiva
Explosive Showdown: Rahul Yadav-Led 4B Networks Clash with Info Edge in High-Stakes Arbitration Battle - Inventiva
The Indian Chief Ministers Are A Bunch Of Crorepatis While The Average Middle-Class Indian Tax Payer Is Struggling To Survive - Inventiva
Top 10 Best Health & Wellness Companies In USA 2023 - Inventiva
Top 20 Best Hardware & Networking Company In India 2023 - Inventiva
Top 10 Best Law Firms In India 2023. - Inventiva
Top 10 Best LegalTech companies in India 2023 - Inventiva
An Interesting Telecom Startup Announced Funding Of INR 30 Crore - Inventiva
TCS, Infosys, Wipro Hire Over 1 Lakh Employees This Fiscal. Know Details - Inventiva
8 US equities have commenced trading on the NSE IFSC in GIFT City; All information about how to start trading through IFSC and should you put money in US stocks? - Inventiva
Innovation And Technology Revolutionizing The Legal Landscape In India 2022 - Inventiva
India Has Its First Most Awaited International Arbitration Centre In Hyderabad In 2021. - Inventiva
The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa - Yahoo Finance
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer I - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Inventiva Adr Stock (IVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):